Dashboard
1
The company has declared positive results in Jan 70 after 7 consecutive negative quarters
- RAW MATERIAL COST(Y) Fallen by -161.23% (YoY)
- NET SALES(Q) Highest at CNY 84.78 MM
- OPERATING PROFIT(Q) Highest at CNY 17.18 MM
2
With ROE of -25.40%, it has a risky valuation with a 8.26 Price to Book Value
3
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,070 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.41
-13.35%
7.85
Revenue and Profits:
Net Sales:
48 Million
(Quarterly Results - Mar 2026)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.81%
0%
20.81%
6 Months
17.4%
0%
17.4%
1 Year
31.59%
0%
31.59%
2 Years
61.55%
0%
61.55%
3 Years
46.93%
0%
46.93%
4 Years
29.63%
0%
29.63%
5 Years
123.83%
0%
123.83%
Hainan Shuangcheng Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.31%
EBIT Growth (5y)
-12.91%
EBIT to Interest (avg)
-6.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.32
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.26
EV to EBIT
-35.68
EV to EBITDA
-94.73
EV to Capital Employed
5.91
EV to Sales
20.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.56%
ROE (Latest)
-25.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
48.40
107.90
-55.14%
Operating Profit (PBDIT) excl Other Income
2.50
32.90
-92.40%
Interest
2.30
2.40
-4.17%
Exceptional Items
0.10
-0.40
125.00%
Consolidate Net Profit
-0.60
16.20
-103.70%
Operating Profit Margin (Excl OI)
52.40%
173.00%
-12.06%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -55.14% vs 27.24% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -103.70% vs 2.53% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
275.70
168.40
63.72%
Operating Profit (PBDIT) excl Other Income
72.50
-16.30
544.79%
Interest
9.70
9.30
4.30%
Exceptional Items
-2.70
-29.00
90.69%
Consolidate Net Profit
8.90
-106.30
108.37%
Operating Profit Margin (Excl OI)
62.90%
-426.10%
48.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 63.72% vs -28.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 108.37% vs -47.64% in Dec 2024
About Hainan Shuangcheng Pharmaceuticals Co., Ltd. 
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






